Ligand id: 9847

Name: fontolizumab

No information available.
Summary of Clinical Use
Fontolizumab (HuZAF) has completed Phase 2 clinical trial in patients with moderate to severe Crohn's disease (NCT00072943). Results showed that fontolizumab was well tolerated by these patients, and effected increased rates of clinical response and remission compared with placebo [2-3]. A Phase 2 trial in rheumatoid arthritis (NCT00281294) was terminated early because the first phase failed to meet the endpoint.